Sagimet Biosciences Inc.
NASDAQ:SGMTBiotechnology
+$0.09 today
- Market cap
- $711.15M
- Beta
- 3.44
- P/E (TTM)
- -5.0
- EPS (TTM)
- -$1.34
Volume 0.93M
Average 1.49M
SGMT Common Stock
The par or stated value of issued common shares, plus paid-in capital where reported together.
Sagimet Biosciences Inc.NASDAQ: SGMT
Common Stock · Q1 FY2026 · quarter ended Mar 2026
Common stock broadly unchanged from a year ago
Common stock stood at $3K at the end of Q1 FY2026, up 0.0% from a year earlier and up 0.0% from the prior quarter. Over 3 fiscal years it compounded at +44.2% a year.
Context
- Common stock amounted to 0.0% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
- Common stock increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether common stock keeps rising in the next quarterly balance sheet after a +0.0% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Common Stock history
USD · from the balance sheet
- Latest · FY2025
- 3K USD
- Year-over-year change
- +0.0%
- 4-year CAGR
- +31.6%
| Period | Period end | Common Stock | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 3K | +0.0% |
| FY2024 | 2024-12-31 | 3K | +50.0% |
| FY2023 | 2023-12-31 | 2K | +100.0% |
| FY2022 | 2022-12-31 | 1K | +0.0% |
| FY2021 | 2021-12-31 | 1K | — |
Common Stock vs competitors
How SGMT compares with its peers on the latest reported figures
- SGMT's Mar 2026 common stock of $3K is the lowest of the 11 companies compared; the peer median is $25.5K.
- Its year-over-year change of +0.0% is the 8th highest of 11, against a peer median of +13.3%.
- Common stock amounts to 0.0% of total assets for SGMT, versus a peer median of 0.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $64.69M | +179666.6% | +34.8% | 0.0% | |
| Mar 2026 | $121K | +17.5% | +11.6% | 0.4% | |
| Mar 2026 | $80K | -5.9% | -2.0% | 0.0% | |
| Mar 2026 | $60K | +9.1% | +15.8% | 0.0% | |
| Mar 2026 | $28K | +3.7% | +1.2% | 0.0% | |
| Mar 2026 | $23K | +43.8% | +26.0% | 0.0% | |
| Mar 2026 | $16K | +100.0% | +58.7% | 0.0% | |
ZURAZura Bio Limited | Mar 2026 | $9K | +28.6% | — | 0.0% |
| Mar 2026 | $6K | +0.0% | +14.5% | 0.0% | |
| Mar 2026 | $4K | +0.0% | +10.1% | 0.0% | |
SGMTSagimet Biosciences Inc. | Mar 2026 | $3K | +0.0% | +44.2% | 0.0% |
| Peer median (excluding SGMT) | $25.5K | +13.3% | +14.5% | 0.0% | |
Competitors are the stored peer set for SGMT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Sagimet Biosciences Inc.
NASDAQ:SGMT
Intrinsic Alpha fair value
Locked
Current Price
$10.11
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.